MTOR and hypertriglyceridemia: In human patients treated with rapamycin and its derivative mTOR inhibitor, everolimus, moderate hypertriglyceridemia and mild to moderate hypercholesterolemia are relatively common while severe hypertriglyceridemia is rare (42, 48–51).